48 Background. Nucleic acid amplification tests (NAATs) are the primary means of 49 identifying acute infections caused by severe acute respiratory syndrome coronavirus 2 50 (SARS-CoV-2). Accurate and fast test results may permit more efficient use of protective and 51 isolation resources and allow for rapid therapeutic interventions. 52 Methods. We evaluated the analytical and clinical performance characteristics of the Xpert ® 53 Xpress SARS-CoV-2 (Xpert) test, a rapid, automated molecular test for SARS-CoV-2. 54 Analytical sensitivity and specificity/interference were assessed with infectious SARS-CoV-2, 55 other infectious coronavirus species including SARS-CoV, and 85 nasopharyngeal swab 56 specimens positive for other respiratory viruses including endemic human coronaviruses 57 (hCoVs). Clinical performance was assessed using 483 remnant upper and lower respiratory 58 specimens previously analyzed by standard of care (SOC) NAATs. 59 Results. The limit of detection of the Xpert test was 0.01 plaque forming units (PFU)/mL. 60 Other hCoVs, including Middle East Respiratory Syndrome coronavirus, were not detected by 61 the Xpert test. SARS-CoV, a closely related species in the Sarbecovirus subgenus, was 62 detected by a broad-range target (E) but was distinguished from SARS-CoV-2 (SARS-CoV-2-63 specific N2 target). Compared to SOC NAATs, the positive agreement of the Xpert test was 64 219/220 (99.5%) and the negative agreement was 250/261 (95.8%). A third tie-breaker 65 NAAT resolved all but three of the discordant results in favor the Xpert test. 66 Conclusions. The Xpert test provided sensitive and accurate detection of SARS-CoV-2 in a 67 variety of upper and lower respiratory tract specimens. The high sensitivity and fast time to 68 results of approximately 45 minutes may impact patient management. 69 70 Laboratory diagnosis of infections caused by severe acute respiratory syndrome coronavirus 2 72 (SARS-CoV-2) is usually accomplished by performing nucleic acid amplification tests 73 (NAATs) on respiratory tract specimens. An antibody response is often not detected in the 74 first week to ten days of symptoms and antibody testing is therefore generally unhelpful for 75 acute diagnosis(1-3), with virus isolation in culture presenting significant biosafety risks. 76 Upper respiratory tract (URT) specimens such as nasopharyngeal swabs (NPS) and 77 oropharyngeal swabs (OPS) generally have high SARS-CoV-2 viral loads upon symptom 78 onset.(2, 4-6) URT specimens may also have detectable RNA during the pre-symptomatic 79 period(7), and pediatric patients who remain asymptomatic through the entire course of 80 on June 9, 2020 by guest http://jcm.asm.org/ Downloaded from 4 infection can persistently shed RNA in URT specimens for two weeks or longer.(4, 8) 81 Importantly, NPS may have higher viral loads than OPS.(6) Lower respiratory tract (LRT) 82 specimens including sputum(7, 9) and tracheal aspirates(10) (TA) are often positive for RNA 83 early in disease and remain positive longer than URT sources.(5) 84 NAATs are...
Group C rotaviruses were detected by reverse transcription-PCR in 14 (2.3%) of 611 group A rotavirusnegative stool specimens from the patients admitted to the International Centre for Diarrhoeal Disease Research, Bangladesh hospital, Dhaka, Bangladesh, during July to December 2003. The low rate of detection suggested that infection with group C rotaviruses was an uncommon cause of hospitalization due to gastroenteritis. In addition, coinfections with pathogenic enteric bacteria were frequently observed in group C rotavirus-infected patients. Nucleotide sequence comparison of the VP4, VP6, and VP7 genes revealed that the Bangladeshi group C rotaviruses were most similar to Nigerian group C rotavirus strains. Phylogenetic analysis suggested that all human group C rotaviruses, including the strains isolated in our study, clustered in a monophyletic branch, which was distantly related to the branch comprised of animal group C rotaviruses.
This study investigates the role of magnesium ions in coupling ATP hydrolysis to the nucleic acid unwinding catalyzed by the NS3 protein encoded by the hepatitis C virus. Analyses of steady-state ATP hydrolysis rates at various RNA and magnesium concentrations were used to determine values for the 15 dissociation constants describing the formation of a productive enzyme-metal-ATP-RNA complex and the 4 rate constants describing hydrolysis of ATP by the possible enzyme-ATP complexes. These values coupled with direct binding studies, specificity studies and analyses of sitedirected mutants reveal only one ATP binding site on HCV helicase centered on the catalytic base Glu291. An adjacent residue, Asp290, binds a magnesium ion that forms a bridge to ATP, reorienting the nucleotide in the active site. RNA stimulates hydrolysis while decreasing the affinity of the enzyme for ATP, magnesium, and MgATP. The binding scheme described here explains the unusual regulation of the enzyme by ATP that has been reported previously. Binding of either free magnesium or free ATP to HCV helicase competes with MgATP, the true fuel for helicase movements, and leads to slower hydrolysis and nucleic acid unwinding. KeywordsATPase; Metal Ions; Viral RNA Replication; Enzyme Mechanism Helicases are motor proteins that travel along nucleic acid tracks to separate a double helix, rearrange secondary structures, assist homologous strand exchange, or strip proteins from DNA or RNA. All known helicases are fueled by the hydrolysis of nucleoside triphosphates (NTPs) in a process that is assisted by divalent metal cations. ATP binds helicases at a Walker-type (P-loop) nucleotide-binding site that is formed by two conserved sequence motifs. 1 The helicase examined in this study is encoded by the hepatitis C virus (HCV). HCV is a positivesense RNA virus that encodes a large polyprotein that is processed into both structural and non-structural proteins. The non-structural HCV proteins form a viral replicase that synthesizes new viral RNA directly from RNA templates. The HCV helicase is required for HCV replication most likely by virtue of its ability to track along RNA and resolve double stranded intermediates as it does in vitro ,2 as evidenced by the fact that HCV helicase stimulates the HCV RNA polymerase, 3 and because subgenomic replicons without a functional helicase synthesize and process viral polyproteins but fail to synthesize additional RNA. 4 There are
Background:The mechanism of repression of inflammasome caused by Francisella tularensis is not known. Results: F. tularensis represses AIM2 and NLRP3 inflammasomes in a FTL_0325-dependent fashion. Conclusion: Repression of inflammasome by F. tularensis results in fulminate infection.Significance: This study advances the understanding of mechanisms of immune suppression caused by F. tularensis.
Francisella tularensis is a facultative intracellular pathogen, and is the causative agent of a fatal human disease known as tularemia. F. tularensis is classified as a Category A Biothreat agent by the CDC based on its use in bioweapon programs by several countries in the past and its potential to be used as an agent of bioterrorism. No licensed vaccine is currently available for prevention of tularemia. In this study, we used a novel approach for development of a multivalent subunit vaccine against tularemia by using an efficient tobacco mosaic virus (TMV) based delivery platform. The multivalent subunit vaccine was formulated to contain a combination of F. tularensis protective antigens: OmpA-like protein (OmpA), chaperone protein DnaK and lipoprotein Tul4 from the highly virulent F. tularensis SchuS4 strain. Two different vaccine formulations and immunization schedules were used. The immunized mice were challenged with lethal (10xLD100) doses of F. tularensis LVS on day 28 of the primary immunization and observed daily for morbidity and mortality. Results from this study demonstrate that TMV can be used as a carrier for effective delivery of multiple F. tularensis antigens. TMV-conjugate vaccine formulations are safe and multiple doses can be administered without causing any adverse reactions in immunized mice. Immunization with TMV-conjugated F. tularensis proteins induced a strong humoral immune response and protected mice against respiratory challenges with very high doses of F. tularensis LVS. This study provides a proof-of-concept that TMV can serve as a suitable platform for simultaneous delivery of multiple protective antigens of F. tularensis. Refinement of vaccine formulations coupled with TMV-targeting strategies developed in this study will provide a platform for development of an effective tularemia subunit vaccine as well as a vaccination approach that may broadly be applicable to many other bacterial pathogens.
Francisella tularensis is the causative agent of a fatal human disease, tularemia. F. tularensis was used in bioweapon programs in the past and is now classified as a category A select agent owing to its possible use in bioterror attacks. Despite over a century since its discovery, an effective vaccine is yet to be developed. In this study four transposon insertion mutants of F. tularensis live vaccine strain (LVS) in Na/H antiporter (FTL_0304), aromatic amino acid transporter (FTL_0291), outer membrane protein A (OmpA)-like family protein (FTL_0325) and a conserved hypothetical membrane protein gene (FTL_0057) were evaluated for their attenuation and protective efficacy against F. tularensis SchuS4 strain. All four mutants were 100–1000 fold attenuated for virulence in mice than parental F. tularensis. Except for the FTL_0304, single intranasal immunization with the other three mutants provided 100% protection in BALB/c mice against intranasal challenge with virulent F. tularensis SchuS4. Differences in the protective ability of the FTL_0325 and FTL_0304 mutant which failed to provide protection against SchuS4 were investigated further. The results indicated that an early pro-inflammatory response and persistence in host tissues established a protective immunity against F. tularensis SchuS4 in the FTL_0325 immunized mice. No differences were observed in the levels of serum IgG antibodies amongst the two vaccinated groups. Recall response studies demonstrated that splenocytes from the FTL_0325 mutant immunized mice induced significantly higher levels of IFN-γ and IL-17 cytokines than the FTL_0304 immunized counterparts indicating development of an effective memory response. Collectively, this study demonstrates that persistence of the vaccine strain together with its ability to induce an early pro-inflammatory innate immune response and strong memory responses can discriminate between successful and failed vaccinations against tularemia. This study describes a live attenuated vaccine which may prove to be an ideal vaccine candidate for prevention of respiratory tularemia.
Francisella tularensis is a Category A Biodefense agent that causes a fatal human disease known as tularemia. The pathogenicity of F. tularensis depends on its ability to persist inside host immune cells primarily by resisting an attack from host-generated reactive oxygen and nitrogen species (ROS/RNS). Based on the ability of F. tularensis to resist high ROS/RNS levels, we have hypothesized that additional unknown factors act in conjunction with known antioxidant defenses to render ROS resistance. By screening a transposon insertion library of F. tularensis LVS in the presence of hydrogen peroxide, we have identified an oxidant sensitive mutant in putative EmrA1 (FTL_0687) secretion protein. The results demonstrate that the emrA1 mutant is highly sensitive to oxidants and several antimicrobial agents, and exhibits diminished intramacrophage growth that can be restored to wild type F. tularensis LVS levels either by transcomplementation, inhibition of ROS generation, or infection in NADPH oxidase deficient (gp91Phox−/−) macrophages. The emrA1 mutant is attenuated for virulence, which is restored by infection in gp91Phox−/− mice. Further, EmrA1 contributes to oxidative stress resistance by affecting secretion of Francisella antioxidant enzymes SodB and KatG. This study exposes unique links between transporter activity and the antioxidant defense mechanisms of F. tularensis.
Background . The increased transmission of SARS-CoV-2 variants of concern (VOC) which originated in the United Kingdom (B.1.1.7/alpha), South Africa (B1.351/Beta), Brazil (P.1/Gamma), in the United States (B.1.427/429 or Epsilon) and in India (B.1.617.2/Delta) requires a vigorous public health response, including real time strain surveillance on a global scale. Although genome sequencing is the gold standard for identifying these VOCs, it is time consuming and expensive. Here, we describe a simple, rapid and high-throughput reverse-transcriptase PCR (RT-PCR) melting temperature (Tm) screening assay that identifies the first three major VOCs. Methods. RT-PCR primers and four sloppy molecular beacon (SMB) probes were designed to amplify and detect the SARS-CoV-2 N501Y (A23063T) and E484K (G23012A) mutations and their corresponding wild type sequences. After RT-PCR, the VOCs were identified by a characteristic Tm of each SMB. Assay optimization and testing was performed with RNA from SARS-CoV-2 USA WA1/2020 (WT), B.1.1.7 and B.1.351 variant strains. The assay was then validated using clinical samples. Results. The limit of detection (LOD) for both the WT and variants was 4 and 10 genomic copies/reaction for the 501 and 484 codon assays, respectively. The assay was 100% sensitive and 100% specific for identifying the N501Y and E484K mutations in cultured virus and in clinical samples as confirmed by Sanger sequencing. Conclusion. We have developed an RT-PCR melt screening test for the major VOCs which can be used to rapidly screen large numbers of patient samples providing an early warning for the emergence of these variants and a simple way to track their spread.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.